EUVIMEDEUVIMED entdecken
Crossref

Fully Synthetic TF-Based Self-Adjuvanting Vaccine Simultaneously Triggers iNKT Cells and Mincle and Protects Mice against Tumor Development

Deying Yang, Xiaohui Li, Jinmei Li, Zichun Liu, Tongtong Li, Pan Liao, Xiang Luo iD, Zhongqiu Liu iD, Wenbo Ming, Guochao Liao iD

Journal of Medicinal Chemistry · 10.10.2024 · 67 (19) · 17640-17656

DOI: 10.1021/acs.jmedchem.4c01631 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 20.09.2024. Verfasst von Deying Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International …. Hauptthemen laut MEDLINE: Cancer Vaccines, Lectins, C-Type, Natural Killer T-Cells. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Guangdong Provincial Department of Science and Technology, Basic and Applied Basic Research Foundation of Guangdong Province, Guangdong Provincial Pearl River Talents Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Thomsen-Friedenreich (TF) antigen has proven to be a promising target for developing novel therapeutic cancer vaccines. Here, a new strategy that TF antigen covalently coupled with KRN7000 and vizantin was developed. The resulting three-component vaccine KRN7000-TF-vizantin simultaneously triggers invariant natural killer T (iNKT) cells and macrophage-inducible C-type lectin (Mincle) signaling pathways, eliciting much stronger TF-specific immune responses than glycoprotein vaccine TF-KLH/alum and the corresponding two-component conjugate vaccines TF-KRN7000 and TF-vizantin. The analysis of IgG isotypes and the secretion of cytokines revealed that KRN7000-TF-vizantin induced Th1/Th2 mixed immune responses, where Th1 was dominant. In vivo experiments demonstrated that KRN7000-TF-vizantin increased the survival rate and survival time of tumor-challenged mice, and surviving mice rejected further tumor attacks without any additional treatment. This work demonstrates that covalently coupled KRN7000 and vizantin could serve as a promising TF-based vaccine carrier for antitumor immune therapy, and KRN7000-TF-vizantin features great potential to be a vaccine candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesLectins, C-TypeNatural Killer T-CellsAnimalsMiceAntigens, Tumor-Associated, CarbohydrateMice, Inbred C57BLFemaleMembrane ProteinsAdjuvants, ImmunologicAdjuvants, VaccineVaccines, SyntheticCell Line, Tumor

Substanzen

Cancer VaccinesLectins, C-TypeClecsf8 protein, mouseAntigens, Tumor-Associated, CarbohydrateThomsen-Friedenreich antigenMembrane ProteinsAdjuvants, ImmunologicAdjuvants, VaccineVaccines, Synthetic

Autor:innen und Institutionen

  • Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of…
  • Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China.
  • Guangzhou Yuemei Pharmaceutical Technology Co., Ltd., Guangzhou 510535, China.

ORCID-Profile: Xiang Luo, Zhongqiu Liu, Guochao Liao

Förderung

  • Guangdong Provincial Department of Science and Technology
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Guangdong Provincial Pearl River Talents Program
  • Guangzhou Municipal Science and Technology Program key projects
  • Guangdong Special Support Plan
  • National Natural Science Foundation of China
  • Basic and Applied Research Project of Guangzhou
  • Key Laboratory of Guangdong Provincial Food and Drug Administration

Zitieren

APA

Yang, D., Li, X., Li, J., Liu, Z., Li, T., Liao, P., Luo, X., Liu, Z., Ming, W., & Liao, G. (2024). Fully Synthetic TF-Based Self-Adjuvanting Vaccine Simultaneously Triggers iNKT Cells and Mincle and Protects Mice against Tumor Development. Journal of Medicinal Chemistry, 67(19), 17640-17656. https://doi.org/10.1021/acs.jmedchem.4c01631

Vancouver

Yang D, Li X, Li J, Liu Z, Li T, Liao P, et al. Fully Synthetic TF-Based Self-Adjuvanting Vaccine Simultaneously Triggers iNKT Cells and Mincle and Protects Mice against Tumor Development. Journal of Medicinal Chemistry. 2024;67(19):17640-17656. doi:10.1021/acs.jmedchem.4c01631

BibTeX
@article{Yang2024,
  author = {Yang, Deying and Li, Xiaohui and Li, Jinmei and Liu, Zichun and Li, Tongtong and Liao, Pan and Luo, Xiang and Liu, Zhongqiu and Ming, Wenbo and Liao, Guochao},
  title = {Fully Synthetic TF-Based Self-Adjuvanting Vaccine Simultaneously Triggers iNKT Cells and Mincle and Protects Mice against Tumor Development},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {19},
  pages = {17640--17656},
  doi = {10.1021/acs.jmedchem.4c01631}
}
Kostenlos starten →